Derk Jan A. de Groot

4.2k citations

35 papers · 1.4k indexed · h-index 17

Oncology top 5%
Radiology, Nuclear Medicine and Imaging top 5%
Molecular Biology
Surgery
Immunology top 10%

Co-authors: Elisabeth G.E. de Vries Marjolijn N. Lub–de Hooge Frans V. Suurs Steven de Jong Rudolf S.N. Fehrmann Geke A.P. Hospers Harry J.M. Groen Boudewijn van Etten
Topics: Monoclonal and Polyclonal Antibodies Research (8 papers)Radiopharmaceutical Chemistry and Applications (6 papers)Cancer Immunotherapy and Biomarkers (6 papers)
Cited by: Oncology Radiology, Nuclear Medicine and Imaging Immunology
Journals: SHILAP Revista de lepidopterologíaCancer Research Clinical Cancer Research
Partner nations: Netherlands Germany Spain

In The Last Decade

Derk Jan A. de Groot

33 papers receiving 1.4k citations

Peers

Countries citing papers authored by Derk Jan A. de Groot

Since Specialization

Citations

This map shows the geographic impact of Derk Jan A. de Groot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Derk Jan A. de Groot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Derk Jan A. de Groot more than expected).

Fields of papers citing papers by Derk Jan A. de Groot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Derk Jan A. de Groot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Derk Jan A. de Groot. The network helps show where Derk Jan A. de Groot may publish in the future.

Co-authorship network of co-authors of Derk Jan A. de Groot

This figure shows the co-authorship network connecting the top 25 collaborators of Derk Jan A. de Groot. A scholar is included among the top collaborators of Derk Jan A. de Groot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Derk Jan A. de Groot. Derk Jan A. de Groot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Independent transcriptional patterns reveal biological processes associated with disease-free survival in early colorectal cancer 2024 ·SHILAP Revista de lepidopterología ·(unknown),(unknown),Derk Jan A. de Groot,Jacco J. de Haan,Elisabeth G.E. de Vries,Rodrigo Dienstmann,Steven de Jong,Arkajyoti Bhattacharya,Rudolf S.N. Fehrmann	0
2	Opportunities on the horizon for the management of early colon cancer 2023 ·Critical Reviews in Oncology/Hematology ·(unknown),Jacco J. de Haan,Rudolf S.N. Fehrmann,Elisabeth G.E. de Vries,Derk Jan A. de Groot	4
3	Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment 2023 ·Cancers ·Herman J. Woerdenbag,Peter Olinga,(unknown),(unknown),(unknown),(unknown),(unknown),Frederik J.H. Hoogwater,(unknown),Derk Jan A. de Groot,Maarten W. Nijkamp	16
4	Comparison of [18F]DOPA and [68Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy 2022 ·SHILAP Revista de lepidopterología ·(unknown),Adrienne H. Brouwers,Derk Jan A. de Groot,Johannes Hofland,Annemiek Walenkamp,Tessa Brabander,Wouter T. Zandee,Walter Noordzij	3
5	Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations 2022 ·Molecular Imaging and Biology ·Joyce van Sluis,Walter Noordzij,Elisabeth G.E. de Vries,Iris C. Kok,Derk Jan A. de Groot,Mathilde Jalving,Marjolijn N. Lub–de Hooge,Adrienne H. Brouwers,Ronald Boellaard	4
6	First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody 2021 ·Clinical Cancer Research ·Laura Kist de Ruijter,(unknown),Danique Giesen,Marjolijn N. Lub‐de Hooge,Iris C. Kok,Adrienne H. Brouwers,Sjoerd G. Elias,Margaret Nguyen,Hong Lu,Jourik A. Gietema,Mathilde Jalving,Derk Jan A. de Groot,Olga Vasiljeva,Elisabeth G.E. de Vries	27
7	89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer 2021 ·Annals of Oncology ·Iris C. Kok,(unknown),Pim P. van de Donk,Danique Giesen,Elly L. van der Veen,Marjolijn N. Lub–de Hooge,Adrienne H. Brouwers,T. Jeroen N. Hiltermann,Anthonie J. van der Wekken,(unknown),Wim Timens,Sjoerd G. Elias,Geke A.P. Hospers,Harry J.M. Groen,Wilma Uyterlinde,Bernies van der Hiel,John B.A.G. Haanen,Derk Jan A. de Groot,Mathilde Jalving,Elisabeth G.E. de Vries	71
8	Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial 2020 ·Radiotherapy and Oncology ·Maxime J.M. van der Valk,Corrie A.M. Marijnen,Boudewijn van Etten,Esmée A. Dijkstra,Denise E. Hilling,Elma Meershoek‐Klein Kranenbarg,Hein Putter,Annet G.H. Roodvoets,Renu R. Bahadoer,Tone Fokstuen,Albert J. ten Tije,Jaume Capdevila,Mathijs P. Hendriks,Ibrahim Edhemović,Andrés Cervantes,Derk Jan A. de Groot,Per J. Nilsson,Bengt Glimelius,Cornelis J.�H. van de Velde,Geke A.P. Hospers	129
9	Molecular imaging biomarkers for immune checkpoint inhibitor therapy 2020 ·Theranostics ·Pim P. van de Donk,Laura Kist de Ruijter,Marjolijn N. Lub–de Hooge,Adrienne H. Brouwers,Anthonie J. van der Wekken,Sjoukje F. Oosting,Rudolf S.N. Fehrmann,Derk Jan A. de Groot,Elisabeth G.E. de Vries	68
10	The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm 2020 ·Journal of Nuclear Medicine ·Frans V. Suurs,Grit Lorenczewski,Sabine Stienen,Matthias Friedrich,Elisabeth G.E. de Vries,Derk Jan A. de Groot,(unknown)	15
11	Reconsider radiation exposure from imaging during immune checkpoint inhibitor trials to reduce risk of secondary cancers in long-term survivors? 2020 ·Cancer Treatment Reviews ·(unknown),Derk Jan A. de Groot,Thomas C. Kwee,(unknown),Rudolf S.N. Fehrmann,Elisabeth G.E. de Vries	3
12	89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake 2019 ·Clinical Cancer Research ·(unknown),Stijn J.H. Waaijer,Iris C. Kok,Frans V. Suurs,Adrienne H. Brouwers,C. Willemien Menke‐van der Houven van Oordt,Thijs T. Wind,Jourik A. Gietema,Carolien P. Schröder,(unknown),Annelies Jorritsma‐Smit,Marjolijn N. Lub–de Hooge,Rudolf S.N. Fehrmann,Derk Jan A. de Groot,Elisabeth G.E. de Vries	42
13	Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study 2019 ·World Journal of Surgical Oncology ·(unknown),Patrick Hemmer,Anna K.L. Reyners,Derk Jan A. de Groot,Robert J. van Ginkel,Lukas B. Been,Geertruida H. de Bock,Barbara L. van Leeuwen	15
14	RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer 2019 ·Molecular Oncology ·(unknown),Lindsay Angus,C. Willemien Menke‐van der Houven van Oordt,Daniëlle A.M. Heideman,Eline Boon,Suzanne C. van Es,Sandra A. Radema,Carla M.L. van Herpen,Derk Jan A. de Groot,Elisabeth G.E. de Vries,Maurice P.H.M. Jansen,Stefan Sleijfer,Henk M.W. Verheul	33
15	Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database 2018 ·American Journal Of Pathology ·(unknown),Rudolf S.N. Fehrmann,Bert van der Vegt,Elisabeth G.E. de Vries,Derk Jan A. de Groot	37
16	Expanding the use of approved drugs: The CPCT’s Drug Rediscovery Protocol (DRUP) 2017 ·Annals of Oncology ·Emile E. Voest,Daphne van der Velden,Louisa R. Hoes,Haiko J. Bloemendal,Katrien Grünberg,Alwin D. R. Huitema,Elly Lugtenburg,Filip De Vos,C. van Herpen,Derk Jan A. de Groot,Paul Hamberg,Egbert F. Smit,Edwin Cuppen,Neeltje Steeghs,Stefan Sleijfer,Henk M.W. Verheul,Hans Gelderblom,Hanneke van der Wijngaart	0
17	Theranostics Using Antibodies and Antibody-Related Therapeutics 2017 ·Journal of Nuclear Medicine ·(unknown),Danique Giesen,Iris C. Kok,Derk Jan A. de Groot,Mathilde Jalving,Rudolf S.N. Fehrmann,Marjolijn N. Lub–de Hooge,Adrienne H. Brouwers,Elisabeth G.E. de Vries	76
18	Data-Driven Prioritization and Review of Targets for Molecular-Based Theranostic Approaches in Pancreatic Cancer 2017 ·Journal of Nuclear Medicine ·Marjory Koller,Elmire Hartmans,Derk Jan A. de Groot,(unknown),Gooitzen M. van Dam,Wouter B. Nagengast,Rudolf S.N. Fehrmann	12
19	Rectal and colon cancer: Not just a different anatomic site 2015 ·Cancer Treatment Reviews ·K Tamás,Anna Maria Elisabeth Walenkamp,Elisabeth G.E. de Vries,Marcel A.T.M. van Vugt,Geerard L. Beets,Boudewijn van Etten,Derk Jan A. de Groot,Geke A.P. Hospers	248
20	Proteasome inhibitor MG132 sensitizes HPV‐positive human cervical cancer cells to rhTRAIL‐induced apoptosis 2005 ·International Journal of Cancer ·(unknown),John H. Maduro,Ate G.J. van der Zee,Derk Jan A. de Groot,Fiona A.J. van den Heuvel,Elisabeth G.E. de Vries,Steven de Jong	48

About Derk Jan A. de Groot

Derk Jan A. de Groot is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Geriatrics and Gerontology, having authored 35 papers that have together received 1.4k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (8 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). The work is most often cited by research in Oncology (865 citations), Radiology, Nuclear Medicine and Imaging (401 citations) and Immunology (218 citations). Derk Jan A. de Groot has collaborated with scholars based in Netherlands, Germany and Spain. Frequent co-authors include Elisabeth G.E. de Vries, Marjolijn N. Lub–de Hooge, Frans V. Suurs, Steven de Jong, Rudolf S.N. Fehrmann, Geke A.P. Hospers, Harry J.M. Groen, Boudewijn van Etten, K Tamás and Marcel A.T.M. van Vugt. Their work appears in journals such as SHILAP Revista de lepidopterología, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact